[A21-26] Tucatinib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.09.2021
Project no.:
A21-26
Commission:
Commission awarded on 12.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-102 | Tucatinib (breast cancer) - Addendum to Commission A21-26 | Commission completed |
Federal Joint Committee (G-BA)
2021-09-02 A G-BA decision was published.